mTOR inhibitors are recommended for renal AML [105], and while no established therapy exists for renal cysts, Siroky et al. (2017) utilized mTOR inhibitors in 15 tuberous sclerosis patients with renal cysts and reported a 71% decrease in kidney volume [111]. Here, MTOR is linked to cystic kidney disease.